Osilodrostat (Isturisa)
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild Autonomous Cortisol Secretion (MACS)
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Trial Timeline
Feb 2, 2026 → Mar 1, 2029
NCT ID
NCT07247058About Osilodrostat (Isturisa)
Osilodrostat (Isturisa) is a approved stage product being developed by Recordati for Mild Autonomous Cortisol Secretion (MACS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07247058. Target conditions include Mild Autonomous Cortisol Secretion (MACS).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07247058 | Approved | Recruiting |
Competing Products
20 competing products in Mild Autonomous Cortisol Secretion (MACS)